Last edition
News about " Multiple Ascending Dose "
Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme
Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.
Multiple Ascending Dose | 20/01/2026 | By News Bureau | 306
Silo Pharma Signs LOI with Allucent for Phase I Development of SPC-15
Silo Pharma has executed a Letter of Intent (LoI) with Allucent to support the phase I clinical development of SPC-15, with planned single-ascending dose and multiple-ascending dose studies representing a key clinical milestone for its intranasal treatment targeting PTSD and anxiety disorders.
Multiple Ascending Dose | 31/12/2025 | By News Bureau | 140
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy